| General Information | |
|---|---|
| ZINC ID | ZINC000006717089 |
| Molecular Weight (Da) | 453 |
| SMILES | Cc1nc2c(-c3ccc(Cl)cc3)n(-c3ccccc3Cl)nc2c(=O)n1CC(F)(F)F |
| Molecular Formula | C20Cl2F3N4O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 106.571 |
| HBA | 3 |
| HBD | 0 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 30 |
| LogP | 6.002 |
| Activity (Ki) in nM | 0.6026 |
| Polar Surface Area (PSA) | 52.71 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.976 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 21 |
| Fraction csp3 | 0.15 |
| Ilogp | 3.33 |
| Xlogp3 | 5.21 |
| Wlogp | 6.69 |
| Mlogp | 4.59 |
| Silicos-it log p | 5.18 |
| Consensus log p | 5 |
| Esol log s | -6.19 |
| Esol solubility (mg/ml) | 0.000295 |
| Esol solubility (mol/l) | 0.00000065 |
| Esol class | Poorly sol |
| Ali log s | -6.06 |
| Ali solubility (mg/ml) | 0.000391 |
| Ali solubility (mol/l) | 0.00000086 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.24 |
| Silicos-it solubility (mg/ml) | 0.00000261 |
| Silicos-it solubility (mol/l) | 5.77E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.37 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.11 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -5.436 |
| Logd | 3.797 |
| Logp | 4.016 |
| F (20%) | 0.002 |
| F (30%) | 0.001 |
| Mdck | - |
| Ppb | 97.40% |
| Vdss | 0.427 |
| Fu | 2.03% |
| Cyp1a2-inh | 0.307 |
| Cyp1a2-sub | 0.904 |
| Cyp2c19-inh | 0.877 |
| Cyp2c19-sub | 0.486 |
| Cl | 7.399 |
| T12 | 0.08 |
| H-ht | 0.793 |
| Dili | 0.972 |
| Roa | 0.075 |
| Fdamdd | 0.517 |
| Skinsen | 0.203 |
| Ec | 0.003 |
| Ei | 0.014 |
| Respiratory | 0.204 |
| Bcf | 1.224 |
| Igc50 | 5.053 |
| Lc50 | 6.871 |
| Lc50dm | 6.493 |
| Nr-ar | 0.005 |
| Nr-ar-lbd | 0.424 |
| Nr-ahr | 0.76 |
| Nr-aromatase | 0.851 |
| Nr-er | 0.688 |
| Nr-er-lbd | 0.239 |
| Nr-ppar-gamma | 0.935 |
| Sr-are | 0.877 |
| Sr-atad5 | 0.69 |
| Sr-hse | 0.768 |
| Sr-mmp | 0.661 |
| Sr-p53 | 0.97 |
| Vol | 395.288 |
| Dense | 1.144 |
| Flex | 0.174 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 2 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.416 |
| Synth | 2.638 |
| Fsp3 | 0.15 |
| Mce-18 | 26 |
| Natural product-likeness | -1.588 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |